Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Manisha Balwani(Karolinska University Hospital), Eliane Sardh(Karolinska University Hospital), Paolo Ventura(University of Modena and Reggio Emilia), Paula Aguilera Peiró(Karolinska University Hospital), David C. Rees(Karolinska University Hospital), Ulrich Stölzel(Karolinska University Hospital), D. Montgomery Bissell(Karolinska University Hospital), Herbert L. Bonkovsky(Atrium Health Wake Forest Baptist), Jerzy Windyga(Karolinska University Hospital), Karl E. Anderson(Karolinska University Hospital), Charles Parker(Karolinska University Hospital), Samuel Silver(Karolinska University Hospital), Sioḃán Keel(Karolinska University Hospital), Jiaan‐Der Wang(Karolinska University Hospital), Penelope E. Stein(Karolinska University Hospital), Pauline Harper(Karolinska University Hospital), Daphne Vassiliou(Karolinska University Hospital), Bruce Wang(Karolinska University Hospital), John D. Phillips(Karolinska University Hospital), Aneta Ivanova(Karolinska University Hospital), Janneke G. Langendonk(Karolinska University Hospital), Raili Kauppinen(Karolinska University Hospital), Elisabeth I. Minder(Karolinska University Hospital), Yutaka Horie(Karolinska University Hospital), Craig Penz(Karolinska University Hospital), Jihong Chen(Karolinska University Hospital), Shangbin Liu(Karolinska University Hospital), John J. Ko(Karolinska University Hospital), Marianne T. Sweetser(Karolinska University Hospital), Pushkal Garg(Karolinska University Hospital), Akshay Vaishnaw(Karolinska University Hospital), Jae Bum Kim(Karolinska University Hospital), Amy Simon(Karolinska University Hospital), Laurent Gouya(Karolinska University Hospital)
New England Journal of Medicine
June 10, 2020
Cited by 588Open Access
Full Text

Abstract

BACKGROUND: Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with resultant accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen, is central to the pathogenesis of acute attacks and chronic symptoms in acute hepatic porphyria. Givosiran, an RNA interference therapy, inhibits ALAS1 expression. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned symptomatic patients with acute hepatic porphyria to receive either subcutaneous givosiran (2.5 mg per kilogram of body weight) or placebo monthly for 6 months. The primary end point was the annualized rate of composite porphyria attacks among patients with acute intermittent porphyria, the most common subtype of acute hepatic porphyria. (Composite porphyria attacks resulted in hospitalization, an urgent health care visit, or intravenous administration of hemin at home.) Key secondary end points were levels of ALA and porphobilinogen and the annualized attack rate among patients with acute hepatic porphyria, along with hemin use and daily worst pain scores in patients with acute intermittent porphyria. RESULTS: A total of 94 patients underwent randomization (48 in the givosiran group and 46 in the placebo group). Among the 89 patients with acute intermittent porphyria, the mean annualized attack rate was 3.2 in the givosiran group and 12.5 in the placebo group, representing a 74% lower rate in the givosiran group (P<0.001); the results were similar among the 94 patients with acute hepatic porphyria. Among the patients with acute intermittent porphyria, givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo. Key adverse events that were observed more frequently in the givosiran group were elevations in serum aminotransferase levels, changes in serum creatinine levels and the estimated glomerular filtration rate, and injection-site reactions. CONCLUSIONS: Among patients with acute intermittent porphyria, those who received givosiran had a significantly lower rate of porphyria attacks and better results for multiple other disease manifestations than those who received placebo. The increased efficacy was accompanied by a higher frequency of hepatic and renal adverse events. (Funded by Alnylam Pharmaceuticals; ENVISION ClinicalTrials.gov number, NCT03338816.).


Related Papers

No related papers found

Powered by citation graph analysis